Status: Recruiting
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Participants needed: 80
Trial details
Phase: Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: Children's Oncology GroupUpdated: Jun 5, 2026Locations: 157
Eligibility criteria
Patients must be >= 1 year and < 22 years of age at the time of enrollment [+13]
Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive.... [+45]